Allopurinol: insights from studies of dose–response relationships

References

• Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11:649–662.
   PubMed Web of Science ®Google Scholar
• Robinson PC, Taylor WJ, Dalbeth N. An observational study of gout prevalence and quality of care in a National Australian general practice population. J Rheumatol. 2015;42:1702–1707.
   PubMed Web of Science ®Google Scholar
• Chandratre P, Mallen CD, Roddy E, et al. “You want to get on with the rest of your life”: a qualitative study of health-related quality of life in gout. Clin Rheumatol. 2016;35:1197–1205.
   PubMed Web of Science ®Google Scholar
• Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology. 2010;49:141–146.
   PubMed Web of Science ®Google Scholar
• Vaccher S, Kannangara DR, Baysari MT, et al. Barriers to care in gout: from prescriber to patient. J Rheumatol. 2016;43:144–149.
   PubMed Web of Science ®Google Scholar
• Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. Br Med J. 2008;336:309–312.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen C, Choi H, et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis. 2012;71:1448–1453.
   PubMed Web of Science ®Google Scholar
• Choi JW, Ford ES, Gao X, et al. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the third National health and nutrition examination survey. Arthritis Rheum. 2008;59:109–116.
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301–1311.
   PubMed Web of Science ®Google Scholar
• Neogi T, Jansen TL, Dalbeth N, et al. Gout classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheumatol. 2015;2015(67):2557–2568.
   Web of Science ®Google Scholar
• Dalbeth N, Merriman TR, Stamp LK. Gout. The Lancet. 2016;388:2039–2052. DOI:10.1016/S0140-6736(16)00346-9
   PubMed Web of Science ®Google Scholar
• Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med. 1987;82:421–426.
   PubMedGoogle Scholar
• Kannangara DR, Phipps-Green AJ, Dalbeth N, et al. Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. Ann Rheum Dis. 2016;75:1363–1366.
   PubMed Web of Science ®Google Scholar
• Torres RJ, Puig JG. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis. 2007;2:48.
   PubMed Web of Science ®Google Scholar
• Phipps-Green AJ, Merriman ME, Topless R, et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann Rheum Dis. 2016;75:124–130.
   PubMed Web of Science ®Google Scholar
• Stiburkova B, Miyata H, Zavada J, et al. Novel dysfunctional variant in ABCG2 as a cause of severe tophaceous gout: biochemical, molecular genetics and functional analysis. Rheumatology (Oxford). 2016;55:191–194.
   PubMed Web of Science ®Google Scholar
• Rasheed H, McKinney C, Stamp LK, et al. The Toll-Like Receptor 4 (TLR4) variant rs2149356 and risk of gout in European and polynesian sample sets. Plos One. 2016;11:e0147939.
   PubMed Web of Science ®Google Scholar
• McKinney C, Stamp LK, Dalbeth N, et al. Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. Arthritis Res Ther. 2015;17:288.
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA, Furst DE, Digiacinto JL, et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226–2237.
   PubMed Web of Science ®Google Scholar
• Wood R, Fermer S, Ramachandran S, et al. Patients with gout treated with conventional urate-lowering therapy: association with disease control, health-related quality of life, and work productivity. J Rheumatol. 2016;43:1897–1903. DOI:10.3899/jrheum.151199
   PubMed Web of Science ®Google Scholar
• Gentili A. Advanced imaging of gout. Semin Musculoskelet Radiol. 2003;7:165–174.
   PubMedGoogle Scholar
• Brailsford JF. The radiology of gout. Br J Radiol. 1959;32:472–478.
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29–42. doi:10.1136/annrheumdis-2016-209707.
   PubMed Web of Science ®Google Scholar
• Graf SW, Whittle SL, Wechalekar MD, et al. Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. Int J Rheum Dis. 2015;18:341–351.
   PubMed Web of Science ®Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431–1446.
   PubMed Web of Science ®Google Scholar
• Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol. 2001;28:577–580.
   PubMed Web of Science ®Google Scholar
• Becker MA, Jolly M. Hyperuricemia and associated diseases. Rheum Dis Clin North Am. 2006;32(275–93):v–vi.
   Google Scholar
• Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46:623–644.
   PubMed Web of Science ®Google Scholar
• Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47–56.
   PubMed Web of Science ®Google Scholar
• Wright DF, Duffull SB, Merriman TR, et al. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016;81:277–289.
   PubMed Web of Science ®Google Scholar
• Stocker SL, McLachlan AJ, Savic RM, et al. The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol. 2012;74:477–489.
   PubMed Web of Science ®Google Scholar
• Stocker SL, Graham GG, McLachlan AJ, et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol. 2011;38:904–910.
   PubMed Web of Science ®Google Scholar
• Berlinger WG, Park GD, Spector R. The effect of dietary protein on the clearance of allopurinol and oxypurinol. N Engl J Med. 1985;313:771–776.
   PubMed Web of Science ®Google Scholar
• Day RO, Miners JO, Birkett DJ, et al. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol. 1988;26:423–428.
   PubMed Web of Science ®Google Scholar
• Graham S, Day RO, Wong H, et al. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Br J Clin Pharmacol. 1996;41:299–304.
   PubMed Web of Science ®Google Scholar
• Reiter S, Simmonds HA, Zollner N, et al. Demonstration of a combined deficiency of xanthine oxidase and aldehyde oxidase in xanthinuric patients not forming oxipurinol. Clin Chim Acta. 1990;187:221–234.
   PubMed Web of Science ®Google Scholar
• Roberts RL, Zhang M, Marinaki AM, et al. Does genetic variability in aldehyde oxidase and molybdenum cofactor sulfurase predict nonresponse to allopurinol? Aliment Pharmacol Ther. 2010;32:310–311.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Eger BT, Nishino T, et al. Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol. Nucleosides Nucleotides Nucleic Acids. 2008;27:888–893.
   PubMed Web of Science ®Google Scholar
• Battelli MG, Bolognesi A, Polito L. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. Biochim Biophys Acta. 2014;1842:1502–1517.
   PubMed Web of Science ®Google Scholar
• Elion GB, Kovensky A, Hitchings GH. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 1966;15:863–880.
   PubMed Web of Science ®Google Scholar
• Nishino T, Okamoto K. Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout. J Biol Inorg Chem. 2015;20:195–207.
   PubMed Web of Science ®Google Scholar
• Massey V, Komai H, Palmer G, et al. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem. 1970;245:2837–2844.
   PubMed Web of Science ®Google Scholar
• Walter-Sack I, de Vries JX, Ernst B, et al. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol. J Rheumatol. 1996;23:498–501.
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312–1324.
   PubMed Web of Science ®Google Scholar
• Stamp LK, O’Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63:412–421.
   PubMed Web of Science ®Google Scholar
• Wright DF, Stamp LK, Merriman TR, et al. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. Eur J Clin Pharmacol. 2013;69:1411–1421.
   PubMed Web of Science ®Google Scholar
• Wen CC, Yee SW, Liang X, et al. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther. 2015;97:518–525.
   PubMed Web of Science ®Google Scholar
• Roberts RL, Wallace MC, Phipps-Green AJ, et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 2016. DOI:10.1038/tpj.2015.101
   Google Scholar
• Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646–1650.
   PubMed Web of Science ®Google Scholar
• Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71:1765–1770
   PubMed Web of Science ®Google Scholar
• Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925–934.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11:R46.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Merriman TR, Barclay ML, et al. Impaired response or insufficient dosage? Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout. Semin Arthritis Rheum. 2014;44:170–174.
   PubMed Web of Science ®Google Scholar
• Rashid N, Coburn BW, Wu YL, et al. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol. 2015;42:504–512.
   PubMed Web of Science ®Google Scholar
• Birkett DJ, Miners JO, Valente L, et al. 1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect. Br J Clin Pharmacol. 1997;43:197–200.
   PubMed Web of Science ®Google Scholar
• Birkett DJ, Miners JO, Day RO. 1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect. Br J Clin Pharmacol. 1991;32:238–241.
   PubMed Web of Science ®Google Scholar
• Day RO, Miners J, Birkett DJ, et al. Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol. Br J Clin Pharmacol. 1988;26:429–434.
   PubMed Web of Science ®Google Scholar
• Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981;6:429–453.
   PubMed Web of Science ®Google Scholar
• Emmerson BT, Gordon RB, Cross M, et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol. 1987;26:445–449.
   PubMedGoogle Scholar
• Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19:704–709.
   PubMed Web of Science ®Google Scholar
• Ramasamy SN, Korb-Wells CS, Kannangara DR, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950–2012. Drug Saf. 2013;36:953–980.
   PubMed Web of Science ®Google Scholar
• Peterson GM, Boyle RR, Francis HW, et al. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy. Eur J Clin Pharmacol. 1990;39:419–421.
   PubMed Web of Science ®Google Scholar
• Peterson GM, Sugden JE. Educational program to improve the dosage prescribing of allopurinol. Med J Aust. 1995;162:74–77.
   PubMed Web of Science ®Google Scholar
• Vazquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60:981–983.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007;57:1324–1328.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Barclay ML, O’Donnell JL, et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther. 2011;90:392–398.
   PubMed Web of Science ®Google Scholar
• Aspen Pharma Pty Ltd. Product Information Xyloprim (allopurinol). 2014 cited 2015 Dec 23]. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-01555-3&d=2016020216114622412.
   Google Scholar
• Jordan KM, Cameron JS, Snaith M, et al. British society for rheumatology and British health professionals in rheumatology guideline for the management of gout. Rheumatology. 2007;46:1372–1374.
   PubMed Web of Science ®Google Scholar
• Coburn BW, Bendlin KA, Sayles H, et al. Target serum urate: do gout patients know their goal? Arthritis Care Res. 2016;68:1028–1035.
   Web of Science ®Google Scholar
• Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol. 2014;10:271–283.
   PubMed Web of Science ®Google Scholar
• Graham GG, Kannangara DR, Stocker SL, et al. Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Br J Clin Pharmacol. 2013;76:932–938.
   PubMed Web of Science ®Google Scholar
• Kannangara D, Graham G, Wright D, et al. Treating gout patients with allopurinol: a concentration- or dose-response approach? [Abstract]. Internal Medicine Journal. 2015;45:13.
   Web of Science ®Google Scholar
• Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64:2529–2536.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol. 2016;12:235–242.
   PubMed Web of Science ®Google Scholar
• Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102:4134–4139.
   PubMed Web of Science ®Google Scholar
• Lee MH, Stocker SL, Williams KM, et al. HLA-B*5801 should be used to screen for risk of Stevens-Johnson syndrome in family members of Han Chinese patients commencing allopurinol therapy. J Rheumatol. 2013;40:96–97.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36:1273–1282.
   PubMed Web of Science ®Google Scholar
• Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011;38:1957–1959.
   PubMed Web of Science ®Google Scholar
• Abeles AM. Febuxostat hypersensitivity. J Rheumatol. 2012;39:659.
   PubMed Web of Science ®Google Scholar
• Bardin T, Chales G, Pascart T, et al. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine. 2016;83:314–317.
   PubMed Web of Science ®Google Scholar
• Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27:337–343.
   PubMed Web of Science ®Google Scholar
• Day R, Hung SI, Chung WH. Allopurinol dose relative to renal function and risk of hypersensitivity reactions. Ann Rheum Dis. 2016;75:e21.
   PubMed Web of Science ®Google Scholar
• Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74:2157–2164.
   PubMed Web of Science ®Google Scholar
• Becker MA, MacDonald PA, Hunt BJ, et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27:585–591.
   PubMed Web of Science ®Google Scholar
• Kot TV, Day RO, Brooks PM. Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs? Med J Aust. 1993;159:182–184.
   PubMed Web of Science ®Google Scholar
• Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72:826–830.
   PubMed Web of Science ®Google Scholar
• Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29:406–413.
   PubMed Web of Science ®Google Scholar
• Roughley MJ, Belcher J, Mallen CD, et al. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:90.
   PubMed Web of Science ®Google Scholar
• Strasak AM, Kelleher CC, Brant LJ, et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol. 2008;125:232–239.
   PubMed Web of Science ®Google Scholar
• Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008;58:623–630.
   PubMed Web of Science ®Google Scholar
• Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811–1821.
   PubMed Web of Science ®Google Scholar
• Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9:13–23.
   PubMed Web of Science ®Google Scholar
• Kim SC, Schneeweiss S, Choudhry N, et al. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015;128(6):653.e7–653.e16.
   Web of Science ®Google Scholar
• Rai SK, Burns LC, De Vera MA, et al. The economic burden of gout: a systematic review. Semin Arthritis Rheum. 2015;45:75–80.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007–2008. Arthritis Rheum. 2011;63:3136–3141.
   PubMed Web of Science ®Google Scholar
• Trifiro G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis. 2013;72:694–700.
   PubMed Web of Science ®Google Scholar
• Ting K, Gill TK, Keen H, et al. Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study. Intern Med J. 2016;46:566–573.
   PubMed Web of Science ®Google Scholar
• De Miguel E, Puig JG, Castillo C, et al. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis. 2012;71:157–158.
   PubMed Web of Science ®Google Scholar
• Kimura-Hayama E, Criales-Vera S, Nicolaou S, et al. A pilot study on dual-energy computed tomography for detection of urate deposits in renal transplant patients with asymptomatic hyperuricemia. J Clin Rheumatol. 2014;20:306–309.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, House ME, Aati O, et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout : a dual energy CT study. Ann Rheum Dis. 2015;74:908–911.
   PubMed Web of Science ®Google Scholar
• Yang Q, Guo CY, Cupples LA, et al. Genome-wide search for genes affecting serum uric acid levels: the framingham heart study. Metabolism. 2005;54:1435–1441.
   PubMed Web of Science ®Google Scholar
• Tang W, Miller MB, Rich SS, et al. Linkage analysis of a composite factor for the multiple metabolic syndrome: the national heart, lung, and blood institute family heart study. Diabetes. 2003;52:2840–2847.
   PubMed Web of Science ®Google Scholar
• Wilk JB, Djousse L, Borecki I, et al. Segregation analysis of serum uric acid in the NHLBI family heart study. Hum Genet. 2000;106:355–359.
   PubMed Web of Science ®Google Scholar
• Nath SD, Voruganti VS, Arar NH, et al. Genome scan for determinants of serum uric acid variability. J Am Soc Nephrol. 2007;18:3156–3163.
   PubMed Web of Science ®Google Scholar
• Holland R, McGill NW. Comprehensive dietary education in treated gout patients does not further improve serum urate. Intern Med J. 2015;45:189–194.
   PubMed Web of Science ®Google Scholar
• Nyhan WL. Inherited hyperuricemic disorders. Contrib Nephrol. 2005;147:22–34.
   PubMed Web of Science ®Google Scholar
• Ea HK, Bardin T, Jinnah HA, et al. Severe gouty arthritis and mild neurologic symptoms due to F199C, a newly identified variant of the hypoxanthine guanine phosphoribosyltransferase. Arthritis Rheum. 2009;60:2201–2204.
   PubMed Web of Science ®Google Scholar
• Kurajoh M, Koyama H, Hatayama M, et al. Partial HPRT deficiency with a novel mutation of the HPRT gene in combination with four previously reported variants associated with hyperuricemia. Intern Med. 2015;54:1523–1526.
   PubMed Web of Science ®Google Scholar
• Petru L, Pavelcova K, Sebesta I, et al. Genetic background of uric acid metabolism in a patient with severe chronic tophaceous gout. Clin Chim Acta. 2016;460:46–49.
   PubMed Web of Science ®Google Scholar
• Simkin PA, Hoover PL, Paxson CS, et al. Uric acid excretion: quantitative assessment from spot, midmorning serum and urine samples. Ann Intern Med. 1979;91:44–47.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002;47:610–613.
   PubMed Web of Science ®Google Scholar
• Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron. 1991;59:364–368.
   PubMed Web of Science ®Google Scholar
• Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447–452.
   PubMed Web of Science ®Google Scholar
• Ensembl. 1000 genomes project phase 3: rs2231142. [updated 2015 July; cited 2015 Sep]. Available from: http://asia.ensembl.org/Homo_sapiens/Variation/Population?r=4:88130671-88131671;v=rs2231142;vdb=variation;vf=1507772
   Google Scholar
• Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. Plos Genet. 2009;5:e1000504.
   PubMed Web of Science ®Google Scholar
• Kottgen A, Albrecht E, Teumer A, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45:145–154.
   PubMed Web of Science ®Google Scholar
• Dehghan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372:1953–1961.
   PubMed Web of Science ®Google Scholar
• Matsuo H, Yamamoto K, Nakaoka H, et al. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Ann Rheum Dis. 2016;75:652–659.
   PubMed Web of Science ®Google Scholar
• Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008;40:437–442.
   PubMed Web of Science ®Google Scholar
• Kannangara DR, Ramasamy SN, Indraratna PL, et al. Fractional clearance of urate: validation of measurement in spot urine samples in healthy subjects and gouty patients. Arthritis Res Ther. 2012;14:R189.
   PubMed Web of Science ®Google Scholar
• Garyfallos A, Magoula I, Tsapas G. Evaluation of the renal mechanisms for urate homeostasis in uremic patients by probenecid and pyrazinamide test. Nephron. 1987;46:273–280.
   PubMed Web of Science ®Google Scholar
• Liu S, Perez-Ruiz F, Miner JN. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. Joint Bone Spine. 2016. DOI:10.1016/j.jbspin.2016.04.007
   Google Scholar
• Sorensen LB. Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum. 1965;8:694–706.
   PubMedGoogle Scholar
• Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nature Commun. 2012;3:764.
   PubMed Web of Science ®Google Scholar
• Matsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med. 2009;1:5ra11.
   PubMed Web of Science ®Google Scholar
• Matsuo H, Nakayama A, Sakiyama M, et al. ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci Rep. 2014;4:3755.
   PubMed Web of Science ®Google Scholar
• Stiburkova B, Pavlikova M, Sokolova J, et al. Metabolic syndrome, alcohol consumption and genetic factors are associated with serum uric acid concentration. Plos One. 2014;9:e97646.
   PubMed Web of Science ®Google Scholar
• Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25:39–42.
   PubMed Web of Science ®Google Scholar
• de Lau LM, Koudstaal PJ, Hofman A, et al. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005;58:797–800.
   PubMed Web of Science ®Google Scholar